Distribution Partnering Terms and Agreements in Pharma, Biotech, Deal Making

Posted by Deeksha on April 3rd, 2019

Market Research Hub (MRH) has actively included a new research study titled “Global Distribution Partnering Terms and Agreements in Pharma, Biotech and Diagnostics 2014 to 2019” to its wide online repository. The concerned market is discoursed based on a variety of market influential factors such as drivers, opportunities and restraints. This study tends to inform the readers about the deal making Terms and Agreement scenarios extending up to the period until 2019. In addition, a deep analysis of the structure of distribution agreements with numerous real life case studies.

Get Sample Copy of this Report@ https://www.marketresearchhub.com/enquiry.php?type=S&repid=2222640

The Global Distribution Partnering Terms and Agreements in Pharma, Biotech and Diagnostics 2014-2019 report provides details of the latest distribution agreements announced in the pharmaceutical, biotechnology and diagnostic sectors.

Fully revised and updated, the report provides details of distribution agreements from 2014 to 2019.

The report provides a detailed understanding and analysis of how and why companies enter distribution deals. The majority of deals are multicomponent whereby the licensor retains either a right or option to distribute the resultant product of the research collaboration. There are also numerous pure distribution deals whereby the products originator takes on a distribution partner in order to maximize a products presence in the marketplace.

Understanding the flexibility of a prospective partners negotiated deals terms provides critical insight into the negotiation process in terms of what you can expect to achieve during the negotiation of terms. Whilst many smaller companies will be seeking details of the payments clauses, the devil is in the detail in terms of how payments are triggered contract documents provide this insight where press releases and databases do not.

This report contains a comprehensive listing of over 2,400 distribution deals announced since 2014 as recorded in the Current Agreements deals and alliances database, including financial terms were available, plus links to online copies of actual distribution contract documents as submitted to the Securities Exchange Commission by companies and their partners.

The initial chapters of this report provide an orientation of distribution deal making and business activities. Chapter 1 provides an introduction to the report, whilst chapter 2 provides an overview and analysis of the trends in distribution as well as a discussion on the merits of the type of deal.

Chapter 3 provides an overview of the structure of distribution deals. The chapter includes numerous case studies to enable understanding of both pure distribution deals and multicomponent deals where distribution forms a part.

Chapter 4 provides a review of the leading distribution deals since 2014. Deals are listed by headline value. Where the deal has an agreement contract published at the SEC a link provides online access to the contract via the Current Agreements deals and alliances database.

Chapter 5 provides a comprehensive listing of the top 50 most active distribution dealmaker companies. Each deal title links via Current Agreements deals and alliances database to an online version of the full deal record, and where available, the actual contract document, providing easy access to each deal record on demand. 

Chapter 6 provides a comprehensive and detailed review of distribution deals organized by company A-Z, therapy, technology and industry type signed and announced since 2014 where a contract document is available. Contract documents provide an indepth insight into the actual deal terms agreed between the parties with respect to the distribution deal.

The appendices to the report includes a comprehensive listing of all distribution deals announced since 2014. Each listing is organized as an appendix by company A-Z, stage of development at signing, therapeutic area and industry type. Each deal title links via hyperlink to an online version of the deal record including, where available, the actual contract document.

The report also includes numerous table and figures that illustrate the trends and activities in distribution dealmaking since 2014.

The report includes deals announced by hundreds of life science companies including big pharma such as Abbott, Abbvie, Actavis, Amgen, Astellas, AstraZeneca, Baxter, Bayer, Biogen Idec, BMS, Celgene, Eisai, Eli Lilly, Gilead, GSK, J&J, Kyowa Hakko, Merck, Mitsubishi, Mylan, Novartis, Pfizer, Roche, Sanofi, Shire, Takeda, Teva, and Valeant, amongst many others.

In conclusion, this report provides everything a prospective dealmaker needs to know about distribution alliances. 

Key benefits

Global Distribution Partnering Terms and Agreements in Pharma, Biotech and Diagnostics 2014-2019 report provides the reader with the following key benefits:

In-depth understanding of distribution deal trends since 2014
Analysis of the structure of distribution agreements with numerous real life case studies
Comprehensive access to over 2,400 actual distribution deals entered into by the worlds biopharma companies
Detailed access to actual distribution contracts entered into by leading biopharma companies
Identify the top most actve distribution dealmakers
Insight into the terms included in a distribution agreement, together with real world clause examples
Understand the key deal terms companies have agreed in previous deals 
Undertake due diligence to assess suitability of your proposed deal terms for partner companies

Request Report TOC @ https://www.marketresearchhub.com/report/global-distribution-partnering-terms-and-agreements-in-pharma-biotech-and-diagnostics-2014-to-2019-report.html

Executive Summary

Chapter 1 Introduction

Chapter 2 Trends in distribution dealmaking

2.1. Introduction
2.2. Definition of distribution deals
2.3. Trends in distribution deals since 2014
2.3.1. Distribution dealmaking by year, 2014 to 2019
2.3.2. Distribution dealmaking by phase of development since 2014
2.3.3. Distribution dealmaking by industry sector since 2014
2.3.4. Distribution dealmaking by therapy area since 2014
2.3.5. Distribution dealmaking by technology type since 2014
2.3.6. Distribution dealmaking by most active company since 2014
2.3.7. Attributes of pure distribution deals
2.3.8. Attributes of distribution in multi-component deals
2.4. Aligning partners to make the distribution agreement work

Chapter 3 Overview of distribution deal structure
3.1. Introduction
3.2. Distribution agreement structure
3.3. Example distribution agreements
3.3.1. Case study 1: Zeltiq Aesthetics Advance Medical
3.3.2. Case study 2: QLT ASD Speciality Healthcare
3.4 Distribution rights as part of a wider alliance agreement
3.4.1. Case study 1: Caleco Pharma Natac Biotech
3.4.2. Case study 2: Purdue Pharma Transcept Pharmaceuticals

Chapter 4 Leading distribution deals
4.1. Introduction
4.2. Top distribution deals by value

Chapter 5 Top 50 most active distribution dealmakers
5.1. Introduction
5.2. Top 50 most active distribution dealmakers

Chapter 6 Distribution deals including contracts directory
6.1. Introduction
6.2. Distribution deals with contracts since 2014

Continued…………@@

 

Like it? Share it!


Deeksha

About the Author

Deeksha
Joined: January 3rd, 2019
Articles Posted: 12,334

More by this author